Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.

Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, Palella FJ, Bream JH, Wallace DC, O'Brien SJ.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):111-6. doi: 10.1097/QAI.0b013e3181a324d6.

2.

Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy.

De Luca A, Nasi M, Di Giambenedetto S, Cozzi-Lepri A, Pinti M, Marzocchetti A, Mussini C, Fabbiani M, Bracciale L, Cauda R, Cossarizza A.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):113-20. doi: 10.1097/QAI.0b013e31823daff3..

PMID:
22245716
3.

European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.

Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW, Canter JA.

AIDS. 2011 Jan 2;25(1):37-47. doi: 10.1097/QAD.0b013e32833f9d02.

4.

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.

Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA.

AIDS. 2005 Sep 2;19(13):1341-9.

PMID:
16103764
5.

Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.

Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR; AIDS Clinical Trials Group 384 and A5005s Study Teams.

J Infect Dis. 2008 Mar 15;197(6):858-66. doi: 10.1086/528697. Erratum in: J Infect Dis. 2008 Jun 1;197(11):1630.

PMID:
18419350
6.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
7.

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.

McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, Ganz J, Jasper J, Harrill D, Gerschenson M.

Antivir Ther. 2008;13(5):715-22.

8.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
9.

Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.

Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B.

AIDS. 2001 Sep 28;15(14):1801-9.

PMID:
11579242
10.

Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy.

Nasi M, Guaraldi G, Orlando G, Durante C, Pinti M, Nemes E, Nardini G, Passarino G, Cocchi M, Esposito R, Mussini C, Cossarizza A.

Clin Infect Dis. 2008 Oct 1;47(7):962-8. doi: 10.1086/591706.

PMID:
18752438
11.
12.

Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.

Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, Deleuze J, Morini JP, Gorin I, Calvez V, Dupin N.

J Clin Virol. 2005 May;33(1):60-4.

PMID:
15797366
13.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
14.

Mitochondrial DNA haplogroups influence AIDS progression.

Hendrickson SL, Hutcheson HB, Ruiz-Pesini E, Poole JC, Lautenberger J, Sezgin E, Kingsley L, Goedert JJ, Vlahov D, Donfield S, Wallace DC, O'Brien SJ.

AIDS. 2008 Nov 30;22(18):2429-39. doi: 10.1097/QAD.0b013e32831940bb.

15.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533
16.

Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B; MULTINEKA Study Group.

Clin Infect Dis. 2009 Sep 15;49(6):892-900. doi: 10.1086/605440.

PMID:
19663689
17.

European mitochondrial DNA haplogroups and metabolic disorders in HIV/HCV-coinfected patients on highly active antiretroviral therapy.

Micheloud D, Berenguer J, Guzmán-Fulgencio M, Campos Y, García-Álvarez M, Catalán P, Cosín J, Miralles P, López JC, Resino S.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):371-8. doi: 10.1097/QAI.0b013e31822d2629.

PMID:
21792063
18.

Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy.

Guallar JP, Gallego-Escuredo JM, Domingo JC, Alegre M, Fontdevila J, Martínez E, Hammond EL, Domingo P, Giralt M, Villarroya F.

AIDS. 2008 Mar 12;22(5):575-84. doi: 10.1097/QAD.0b013e3282f56b40.

PMID:
18316998
19.

Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

Worm D, Kirk O, Andersen O, Vinten J, Gerstoft J, Katzenstein TL, Nielsen H, Pedersen C.

HIV Med. 2002 Oct;3(4):239-46.

20.

Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

Nolan D, Mallal S.

Sex Health. 2005;2(3):153-63. Review.

PMID:
16335543

Supplemental Content

Support Center